## Amanda Cole

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/564607/publications.pdf

Version: 2024-02-01

1307366 1372474 10 190 7 10 citations g-index h-index papers 11 11 11 368 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.1	70
2	HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS. International Journal of Technology Assessment in Health Care, 2015, 31, 331-338.	0.2	37
3	Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health, 2016, 19, 255-266.	0.1	19
4	A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?. Applied Health Economics and Health Policy, 2017, 15, 469-477.	1.0	16
5	Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE's Medical Technologies Evaluation Programme (MTEP). Applied Health Economics and Health Policy, 2014, 12, 347-357.	1.0	15
6	Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?. Patient, 2020, 13, 599-610.	1.1	12
7	Valuing EQ-5D-5L health states â€~in context' using a discrete choice experiment. European Journal of Health Economics, 2018, 19, 595-605.	1.4	8
8	Digital cognitive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis. BJGP Open, 2022, 6, BJGPO.2021.0146.	0.9	6
9	Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare. International Journal of Environmental Research and Public Health, 2022, 19, 1674.	1.2	4
10	Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. Journal of Comparative Effectiveness Research, 2019, 8, 1045-1054.	0.6	2